COVID-19 Funding News
COVID-19 Funding News - as of January 4, 2021
COVID-19 has presented us with many challenges, but it has and will continue to present new research funding opportunities. Here we list summary information about COVID-19 funding news as well as other new and relevant opportunities that could be used for research with a COVID-19 application.
Overview of Just Passed $900 Billion COVID-19 Relief Bill
Ryan M. Ward, SJSU’s Director of Advocacy and Federal Relations, provides the following details. On December 21, 2020, congressional leaders reached a deal and passed a $900 billion COVID-19 relief bill, along with $1.4 trillion in appropriations legislation to fund the government through the end of fiscal year 2021. The relief bill funds key federal higher education programs, including billions for institutions of higher education as well as statutory changes to the Free Application for Federal Student Aid (FAFSA) and federal Pell Grants. The bill was signed into law on December 27, 2020.
COVID-19 Higher Education Funding: Included in the package is a total of $81.88 billion for K-12 schools, colleges, and universities to prevent, prepare for, and respond to the coronavirus crisis. Included within this is $22.7 billion for institutions of higher education, most of which ($20.2 billion) will go to public and private universities and their students.
The remainder of the higher education funding will go to historically black colleges and universities (HBCUs), tribal colleges and universities, minority-serving institutions (MSIs) - which includes SJSU - and other specific types of institutions and students. By comparison, the CARES Act, which was signed into law in late March, included $14 billion for higher education, $12.5 billion of which was allocated directly to institutions.
For more information, contact Ryan M. Ward.
California Humanities Hosts a Conversation About City-Making Amid COVID-19
From Cal Humanities: “In the midst of the COVID-19 public health crisis and the Black Lives Matter Movement, social issues are exacerbated. Already engaged in the transformation of their cities, a group of artists, urban planners, entrepreneurs, elected officials and researchers embarked on a journey to examine the process of city-making in France and California. The Oakland/Saint-Denis project was born under a common conviction: our cities must be built collectively and with the arts and humanities at the center.” The program is entitled City/ Cité: Two Cities, Two Mayors, One Goal (City/ Cité: Deux villes, deux maires, un objectif) and will be led by Oakland, California Mayor Libby Schaaf and Mayor Mathieu Hanotin from Saint-Denis, France. Register and get more info here for the event on Thursday, January 14, 10-11:30 am PST.
The Fifth U.S. Investigational COVID-19 Vaccine Phase 3 Trial Has Begun
From the National Institutes of Health (NIH) press release: “The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, are funding the trial.”
Part of a collaboration with Operation Warp Speed (OWS), a multi-agency collaboration overseen by HHS and the Department of Defense that aims to accelerate development, manufacture and distribution of medical countermeasures for COVID-19, the vaccine will be administered in two doses, 21 days apart.
People 18 years of age and older can participate in this trial. Participants in high risk categories are encouraged to apply.
“We’ve come this far, this fast, but we need to get to the finish line,” said NIH Director Francis S. Collins, M.D., Ph.D. “That will require multiple vaccines using different approaches to ensure everyone is protected safely and effectively from this deadly disease.
National Institutes of Health (NIH) Enlists Llamas in the Fight Against COVID-19
Everyone is working hard to fight COVID-19 and we all need some levity in this trying time, so here’s a light-hearted yet serious story about NIH neuroscientists studying nanobodies, special types of tiny antibodies naturally produced by the immune systems of camelids (camels, llamas, and alpacas). Previous to the COVID-19 pandemic, Thomas J. “T.J.” Esparza, B.S., and David L. Brody, M.D., Ph.D., were working to improve brain imaging at the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), but the pair switched course to help with the fight against COVID-19.
Now the pair have produced preliminary results suggesting that anti-COVID-19 nanobodies may be effective at preventing and diagnosing infections. A set of promising antibodies, or “nanobodies,” against SARS-CoV-2 were produced by a Bellingham, Washington based llama named Cormac. From the press release: “Preliminary results published in Scientific Reports suggest that at least one of these nanobodies, called NIH-CoVnb-112, could prevent infections and detect virus particles by grabbing hold of SARS-CoV-2 spike proteins. In addition, the nanobody appeared to work equally well in either liquid or aerosol form, suggesting it could remain effective after inhalation. SARS-CoV-2 is the virus that causes COVID-19. Because nanobodies are more stable, less expensive to produce, and easier to engineer than typical antibodies, a growing body of researchers, including Mr. Esparza and Dr. Brody, have been using them for medical research.”
National Institutes of Health (NIH) Awards Over $107 Million to Support Innovative Approaches to COVID-19 Testing and Surveillance
From the press release: “The National Institutes of Health has awarded over $107 million through its RADx Radical (RADx-rad) program” - part of the Rapid Acceleration of Diagnostics (RADx) initiative created to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing - “to support innovative approaches and reimagined uses of existing tools to address gaps in COVID-19 testing and surveillance, and develop platforms that can be deployed quickly during an emerging outbreak of COVID-19 or other infectious disease.”
The first 49 research projects and grant supplements have been awarded to 43 institutions across the United States. These funded projects focus on non-traditional viral screening approaches, new analytical platforms with novel chemistries or engineering, rapid detection strategies, point-of-care devices, and home-based testing technologies. For instance, some examples of these funded projects from the National Institute of Nursing Research (NINR), one of the RADx-rad program partners, include: Multi-modal Wireless COVID Monitoring and Infection Alerts for Concentrated Populations; Reaching Communities through the Design of Information Visualizations (ReDIVis) Toolbox for Return of COVID-19 Results, and Alive Church Network: Increasing COVID-19 Testing in Chicago’s African American Testing Deserts. Learn more about all the types of projects being supported under the RADx-rad program.
COVID-19 Funding Opportunity Announcements Subsiding
Announcements of new funding opportunities for COVID-19 specific projects have greatly subsided, however, you can find a current curated selection online via the Research Foundation.
The Archives: COVID-19 Funding News - as of November 2, 2020
National Institutes of Health (NIH) Reports on the Impact of COVID-19 on Researchers and Outlines Proactive Mitigation Measures
It will come as NO SURPRISE to SJSU researchers that while COVID-19 research has yielded positive results, other research has been very negatively impacted, primarily due to social distancing guidelines. Labs have closed, access to facilities and equipment have been restricted, conferences have been cancelled, supply chains for new equipment have been disrupted, graduations for biomedical students are uncertain, and career proposals for trainees and early career scientists have been delayed. Additionally, U.S. faculty openings have fallen by 70%. Sadly, multiple studies have shown a greater impact has been felt by bench scientists, women scientists, and scientists with young children.
Dr. Michael Lauer, NIH's Deputy Director for Extramural Research, takes up this topic in his Extramural Nexus November 4, 2020 post. “Given these known stresses, and likely more to come, how to proceed? In June, Gibson and colleagues published an interesting essay in which they noted that we should not respond by merely yearning to return back to normal, since the normal state was not that great. They wrote that the pandemic served to highlight long standing problems in academic research, including a complicated system that ‘is catered towards senior-level researchers,’ an observation supported by data from NIH and elsewhere.”
Dr. Lauer continues, “The authors argued that the pandemic offers an ‘unprecedented opportunity to reset,’ with particular attention paid to early career researchers. They offer a number of recommendations: for funders they call for simplification of procedures, policies that decrease dependency on preliminary data, extension of early stage investigator status, and no-cost extensions for existing grants.” Dr. Lauer cites NIH’s work to implement a number of these recommendations including, “plans for the Stephen I. Katz award [pdf], an R01 award for early stage investigators based on applications with no preliminary data allowed; expedited processes for requesting extension of early stage investigator status; revised application and review policies that allow for post-submission of preliminary data and instructions to reviewers to disregard situations directly related to the COVID-19 pandemic, such as temporary declines in productivity, and expedited processes for requesting on a case-by-case basis no-cost extensions for research, career, and training awards.”
National Institutes of Health (NIH) seeks researcher input on NIH’s Strategic Plan for COVID-19 Research
NIH created the first Strategic Plan for COVID-19 Research in July 2020. Per Dr. Michael Lauer, NIH's Deputy Director for Extramural Research, the current plan prioritizes “conducting fundamental research; advancing diagnostics, treatments and prevention strategies; and redressing poor COVID-19 outcomes in health disparity and vulnerable populations. Cutting across all of these priorities is an emphasis on the importance of scientific collaboration, the research workforce, and data science as keys to the response.”
NIH is currently seeking researcher comments and suggestions for the next version of the plan. Read the Request for Information (NOT-OD-21-018), then submit your ideas on this form by December 7, 2020. Dr. Lauer asks that “if you have noted significant research gaps or barriers in the original Plan, let us know. Or perhaps you can share new resources that NIH can leverage to advance one of the plan’s priorities. Maybe a new scientific technique has emerged that could revolutionize COVID-19 research.” NIH would appreciate any of your suggestions.
COVID-19 Funding Opportunity Announcements Subsiding
Announcements of new funding opportunities for COVID-19 specific projects have greatly subsided, however, you can find a current curated selection online via the Research Foundation.
The Archives: Covid-19 Funding News – as of September 18, 2020
Areas Hardest Hit by COVID-19, Including California, Receive NIH Funding for Community Engagement Research Efforts
An award of $12 million for outreach and engagement efforts in ethnic and racial minority communities disproportionately affected by the COVID-19 pandemic was announced last week by The National Institutes of Health (NIH). RTI International, a non-profit research institution, will support teams in 11 states, established as part of the NIH Community Engagement Alliance (CEAL) Against COVID-19 Disparities. Dr. Arleen F. Brown, M.D., Ph.D, from the University of California, Los Angeles, is the PI from the CEAL research team based in California.
The effort will focus on COVID-19 awareness and education research, especially among African Americans, Hispanics/Latinos, and American Indians. Inclusion and participation of these groups in vaccine and therapeutic clinical trials to prevent and treat the disease will also be stressed. The research teams will utilize established relationships between NIH-funded researchers and local community leaders to reach underserved communities. Other states selected to host a CEAL team include Alabama, Arizona, Florida, Georgia, Louisiana, Michigan, Mississippi, North Carolina, Tennessee and Texas.
“Addressing health disparities affecting racial and ethnic minority populations has long been a priority for NIH,” said NIH Director Francis S. Collins, M.D., Ph.D. “The burden of the COVID-19 pandemic borne by diverse communities, especially those that include Blacks and Latinos, makes clear the urgent need for treatments and vaccines that are effective for all Americans. Inclusive research that reflects the entire population is essential to this goal.”
CEAL is an NIH-wide effort led by the National Institute on Minority Health and Health Disparities (NIMHD) and the National Heart, Lung, and Blood Institute (NHLBI).
Cal Humanities Shares (COVID-19) Socially Distanced Humanities Programming on October 1
An exciting invitation was just announced by Cal Humanities: “Learn how recent California Humanities grantees The World According to Sound, Inlandia Institute, Elkhorn Slough, SDFutures Collective, and Oakland Asian Cultural Center are successfully engaging new audiences with online humanities programs. Hear their outreach and engagement strategies and learn what marketing techniques have worked for them. Network with humanities peers and participate in a Q&A with the panelists.”
Sign up for the October 1 (4 to 5:30 pm) zoom conversation entitled Virtual Programs, Real Connections: A Conversation, with six virtual programmers from across the state. Cal Humanities promises that at this session attendees will “learn how peers in cultural, literary, and media organizations are reaching audiences in this age of social distancing; get a snapshot view of various online platforms and formats; facilitate questions in a Q&A, and connect with a network of humanities practitioners in a virtual happy hour.”
Substance Use Disorders (SUD) Linked to COVID-19 Susceptibility
A just-released National Institutes of Health (NIH) funded study finds that certain types of SUDs - tobacco, alcohol, opioid, cannabis, and cocaine - make people more susceptible to COVID-19 and its complications. The research, published on September 14th in Molecular Psychiatry, was co-authored by the National Institute on Drug Abuse’s (NIDA) Dr. Nora D. Volkow, M.D.
The strongest predictors are opioid and tobacco use disorders (in that order). Not only are these patients more likely to get COVID-19, they were found to experience more severe outcomes including hospitalization and death since these patients have compromised lungs and cardiovascular systems. Marginalization also creates additional barriers for these patients to receive medical care. The study was conducted using data from 360 hospitals nationwide.
Compared to whites, African Americans with a recent opioid use disorder diagnosis were four times more likely to develop COVID-19. This is due in part to the fact that risk factors such as hypertension, diabetes, cardiovascular diseases, and renal diseases, are more common among African Americans with opioid use disorder.
From the National Institute on Drug Abuse (NIDA): “The National Institute on Drug Abuse (NIDA) is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. Fact sheets on the health effects of drugs and information on NIDA research and other activities can be found at www.drugabuse.gov.”
The Archives: COVID-19 Funding News - as of August 28, 2020
Time-Sensitive Research Opportunities in Environmental Health Sciences
Understanding the consequences of natural and human-made disasters, emerging environmental public health threats, and related policy changes in the U.S. and abroad is the focus of this National Institute of Environmental Health Sciences opportunity. Outside the traditional scope of medical research, this presents an opportunity to utilize political science and law studies faculty members interested in collaboration. Additionally, partnerships that support this funding opportunity’s projects might include community-based organizations, environmental justice groups, local health and environmental agencies, worker organizations, and others.
This National Institutes of Health (NIH) funding opportunity RFA-ES-19-011 “seeks novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. Applications are due: October 1, 2020,” reports Willette Brown-Fatoyinbo, Program Manager, Grants Resource Center, American Association of State Colleges and Universities.
See ALL of the new and current COVID-19 related funding opportunities on the SJSU RF COVID-19 list.
Different Online Formats for Humanities Programming Explored During COVID-19
“How does COVID-19 impact your work, and what capacity-building needs do you have to help adjust to this new reality?” is the question California Humanities asked of grantees and partners. The answers are helping to support unique and compelling humanities programming through a virtual format during this period of required social distancing. Cal Humanities Art of Storytelling is developing programs to share California stories from throughout the state on far-reaching topics.
Additionally, responses to this question led California Humanities to create plans for virtual convenings and skill-building events in the coming months. On October 1, starting at 4 pm, California Humanities is hosting an online event entitled Virtual Programs, Real Connections: A Conversation that will feature short presentations from grantees from around the state who are experimenting with different types of online and socially-distanced programming formats. A Q&A and general discussion will follow the participants’ remarks. You can register for this event HERE.
Literature and Medicine, A California Humanities Initiative, Helps During COVID-19
The COVID-19 pandemic has caused new and increasing strains on healthcare providers. A California Humanities program that began in 2010, Literature and Medicine is strategically positioned to offer participants relief through space to thoughtfully reflect on their work and connect with their colleagues. California Humanities states, “Literature and Medicine is a humanities-based professional development program for health care workers that engages hospital staff members in reading and discussion programs facilitated by humanities scholars. Through reading, discussion and reflection, Literature and Medicine invites caregivers to engage in productive conversations that help them better understand and increase their empathy with the experience of their patients and their peers.
The benefits of participating in this program have included increasing job satisfaction, lessening burnout, improving communication skills, and building greater capacity for cultural competence among participants. Additionally, many participants have noted that taking part in Literature and Medicine has helped improve the quality of health care they provide for their patients.”
The Archives: COVID-19 Funding News - as of August 11, 2020
COVID-19 Related RSCA Faculty Tapas Talks “Very Engaging”
The first of many SJSU Faculty Tapas Talks to come were held August 5, 2020. They focused on COVID-19 related research topics and were a great success. Over 100 community members attended and 23 short talks were presented by 28 faculty members. Presenting faculty represented all Colleges and the Library. Topics ranged from poetry to bio-medical research with all fields in between. Co-hosted by Research Development and Corporate and Foundation Relations, presenters and audience members were divided into two pitch rooms, each with about twelve five-minute presentations. If you missed the event you can watch the recordings: opening session, pitch room 1, and pitch room 2. The agenda and list of talks for each pitch room are here.
Two more Faculty Tapas Talks are planned for Friday, October 2, and Friday, November 6, with topics TBD. All faculty will receive an e-mail alert and sign up for these events. Please save the dates on your calendar!
Charting a Rapid Course Toward Better COVID-19 Testing
Seven biomedical technology companies will receive a total of $248.7 million in federal stimulus funding to accelerate efforts to scale up new lab-based and point-of-care technologies for fast, easy-to-use tests for COVID-19. Part of the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) - see more about RADx in the July 27 Summary Update below - the 100 best concepts were chosen, and after an intense one-week “shark-tank” technology evaluation process, winners were funded.
NIH just announced the first RADx projects to emerge with flying colors. Point-of-care testing approaches include a 30-minute test from Mesa Biotech; a 15-minute version from Quidel, and a 30-minute test from Talis Biomedical.
Lab-based testing approaches include Ginkgo Bioworks, planning to process tens of thousands of tests simultaneously and delivering results in one to two days; Helix OpCo will process up to 50,000 samples per day by the end of September and 100,000 per day by the end of 2020; Fluidigm plans to process up to tens of thousands of saliva tests per day, and Mammoth Biosciences aims to provide a multi-fold increase in testing capacity in commercial laboratories.
Significant progress is also being made by a public-private partnership called Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), which involves 20 biopharmaceutical companies, academic experts, and multiple federal agencies. This group is working on a variety of trials and studies examining and addressing many areas of need and concern as the effort to get COVID-19 under control continues.
New COVID-19 Emergency Award Opportunities Just Released
The National Institutes of Health (NIH) just published new funding solicitations related to the Rapid Acceleration of Diagnostics (RADx) program. The ones that apply to SJSU are listed below. Note: as quick turnaround emergency awards, most require an LOI due toward the end of August, with a full proposal due in September.
See ALL of the new and current COVID-19 related funding opportunities on the SJSU RF COVID-19 list.
The Archives: COVID-19 Funding News - as of July 27, 2020
Seating Still Available for SJSU Faculty Tapas Talks: COVID-19 Related RSCA, on Wednesday, August 5th, 10:30 am - 1 pm
Space is still available for the co-sponsored and co-hosted Research Development and Corporate and Foundation Relations’ Faculty Tapas Talk on Wednesday, August 5th from 10:30 am to 1 pm. The virtual event will feature faculty from across campus presenting current and future COVID-19 related research. Talks will be 5-minutes each, followed by a short Q&A. The presenter spots have all been filled, but attendance is still open; please fill out this online form to attend; space is limited.
Unprecedented Initiative Ramping up COVID-19 Tests from 1 Million Daily to 6 Million Daily
The National Institutes of Health’s (NIH) Rapid Acceleration of Diagnostics (RADx) initiative will increase diagnostic testing capacity for COVID-19 in the US from the current daily capacity of 1 million tests per day to 6 million tests per day by December 2020. Current diagnostic testing for COVID-19 uses a decades-old technology called PCR, polymerase chain reaction. This technology is time-consuming and needs specialized equipment and sophisticated labs. To rapidly expand access to testing, NIH launched the RADx program in late April 2020, a collaboration between the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense (DOD), supported by $1.5 billion in federal stimulus funding. This effort also seeks to provide testing for underserved populations.
To learn more about the four parts of RADx, all operating on a fast track - the effort has been likened to a scientific “shark tank” - read NIH Director Dr. Francis Collins’ July 23 blog.
New COVID-19 Research Opportunities
A few exciting COVID-19 related funding opportunities, two from the National Science Foundation (NSF), and one from the National Institutes of Health (NIH), and have been posted to the SJSU RF COVID-19 list.
NSF’s Innovative Technology Experiences for Students and Teachers (ITEST) is an applied research and development (R&D) program providing direct student
learning opportunities in pre-kindergarten through high school. The learning opportunities
are based on innovative use of technology to strengthen knowledge and interest in
science, technology, engineering, and mathematics (STEM) and information and communication
technology (ICT) careers. NSF’s Cyber-Physical Systems, provides a research opportunity for engineered systems that are built from, and
depend upon, the seamless integration of computation and physical components.
NIH’s Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional) is also appropriate for COVID-19 related research as patterns of alcohol use impact transmission of HIV, engagement and retention in care, and susceptibility to coinfections (e.g., COVID-19, hepatitis C and tuberculosis).
The Archives: Covid-19 Funding News – as of July 13, 2020
SJSU Faculty Tapas Talks: COVID-19 Related RSCA, August 5th, 10:30 am - 1 pm
In recent years, the Colleges of Science and Engineering have hosted Tapas Talks: short presentations by faculty designed to excite others about their research, foster discussion, and find collaborators. Research Development, jointly with Corporate and Foundation Relations, will support the continuation and expansion of these talks to include faculty from all colleges on various themes.
The first Faculty Tapas Talk will be on Wednesday, August 5th from 10:30 am to 1 pm. This virtual event will feature faculty from across campus presenting current and future COVID-19 related research. Talks will be 5-minutes each, followed by a short Q&A. If you are interested in giving a talk or in attending the event to listen, ask questions, network, and identify new research collaborators, please fill out this online form. At the moment, we are not limiting attendees, but presentation slots are limited and will be prioritized on a first-come, first-served basis with a July 16 cutoff date for presenters to let us know, via the online form, that they want a slot. Please mark your calendars and plan to attend.
New COVID-19 Research Opportunities
A few exciting COVID-19 related funding opportunities from the National Science Foundation (NSF) have been posted to the SJSU RF COVID-19 list. They include an offering from Ecology and Evolution of Infectious Diseases (EEID), a multi-agency program that supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases, and a joint solicitation between NSF and the National Institute for Standards and Technology (NIST) in the form of Disaster Resilience Research Grants (DRRG). DRRG research proposals will advance fundamental understanding of disaster resilience in support of improved, science-based planning, policy, decisions, design, codes, and standards.
NIH’s COVID-19 Vaccine Development Efforts and Clinical Trials
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National
Institutes of Health’s (NIH), has established a new clinical trials network that will enroll tens of thousands of volunteers in large-scale clinical trials testing
a variety of investigational COVID-19 vaccines.
One promising COVID-19 vaccine moving rapidly through the development pipeline is under development by the Dale and Betty Bumpers Vaccine Research Center (VRC). In addition to finding a safe and effective vaccine, biomedical researchers are also devising technologies to speed human testing. On July 9, NIH Director, Dr. Francis Collins, interviewed Dr. John Masdcola, director of VRC.
The Archives: Covid-19 Funding News – as of June 29, 2020
NSF extends Faculty Early Career (CAREER) Development Program Deadline Due to COVID-19
NSF has extended the deadline for its Faculty Early Career Development Program Solicitation (NSF 20-525) for all NSF directorates. The new deadline is Tuesday, August 11, 2020, 5:00 p.m. submitter's local time. See details here.
NIH Announces FOA to Evaluate Community Interventions Addressing COVID-19
A new R01 funding opportunity for research aimed at the psychosocial, sociocultural, behavioral, and socioeconomic impact of COVID-19 on communities historically plagued by health disparities and/or COVID-19 vulnerable populations has just been announced by the National Institutes of Minority Health and Health Disparities (NIMHD), in conjunction with several other NIH Institutes and Centers. See FOA to Evaluate Community Interventions Addressing COVID-19.
NIMHD defines COVID-19 vulnerable populations as follows: residents of chronic care and assisted living facilities; community-dwelling older adults; individuals with cognitive impairment or dementia; homeless populations; incarcerated populations; adults with medical comorbidities; pregnant women; children and adolescents; individuals with substance use disorders or severe mental illness, those living in congregate housing (e.g., shelters, residential treatment, or assisted living); persons who are deaf or with disabilities including visual, hearing, communication, or mobility impairment; detainees in immigration centers; migrant communities; individuals living on tribal lands or reservations; and communities that are exposed to high rates of air pollution or other toxic exposures. Vulnerable groups also include those on the frontlines of healthcare during the COVID-19 pandemic, and those working in essential business operations (e.g., grocery and pharmacy workers, transportation, hospital and community janitorial/sanitation workers, waste collectors, postal and other delivery service workers, warehouse personnel, etc.).
NIH Announces New “N3C” - National COVID Cohort Collaborative - to Aid COVID Researchers
NIH has just announced the launch of a centralized, secure data hub to store and study vast amounts of medical records from people diagnosed with coronavirus disease across the country. It is part of an effort, called the National COVID Cohort Collaborative (N3C), to help scientists analyze these data to understand the disease, and to inform best practices for resource allocation, drug discovery, and treatment options.
The analytics platform will systematically collect scattered patient data - clinical, laboratory, and diagnostic - from health care provider organizations nationwide so data can be harmonized and aggregated into a standard format.
Launched with 35 institutions, N3C is collecting data on COVID-tested patients, including demographics, symptoms, medications, lab test results, and outcomes. The ZIP code of the health care group providing the information and the dates of service are the only personal data included. The data will be open to all approved users and is governed by an oversight committee.
NIH’s All of Us Program Joins Fight Against COVID-19
The All of Us Research Program, another NIH database, may also provide new insights into COVID-19—through antibody testing, a survey on the pandemic’s impacts and collection of electronic health record information. Begun in 2015 during the Obama administration, its goal is to build a data resource containing multi-layered information on one million or more participants who reflect the rich diversity of the United States.
This data will help researchers gain better insights into the biological, environmental, and behavioral factors that influence health as well as accelerating health research and medical breakthroughs. All of Us will make data gathered broadly accessible to approved researchers over time; its data platform, the Researcher Workbench, is now in beta testing. Get more information or sign up.
Recent NIH COVID-19 Research Findings
The Archives: Covid-19 Funding News – as of June 15, 2020
SJSU’s Revitalization and Adaptation Plan for RSCA
A phased restart to RSCA is underway at SJSU. Critical and time-sensitive RSCA activities
will resume first and must be approved by submitting a RSCA Project Plan form.
The SJSU RSCA Revitalization and Adaptation Plan was created in coordination with the CSU, county, state, and national guidelines. The plan has four phases; since May 22, 2020, we are in phase 2. The plan outlines the principles guiding the phased approach to adaptation and the implementation details of each phase - the text and required forms can be found on the Division of Research and Innovation web pages.
Watch the June 4th presentation of the Plan by Dr. Mohamed Abousalem, Vice President for Research and Innovation, Dr. Pam Stacks, Associate Vice President of Research, and Dr. Julia Gaudinski, Director of Research Development.
Please note that the SJSU administration is keenly aware of the impact this pandemic has had on the RSCA work on campus. We hope this plan will help us mitigate further impact to the safest possible extent.
We thank the faculty, staff and community for your patience and your flexibility as we work together to resume our activities during these extraordinary times.
Research During COVID-19
Summer is a great time to write a research proposal and the Research Development Team
can help you write strategic proposals that address research challenges associated
with the current COVID-19 environment, as well as coronavirus contingency mitigations.
Research Development Office Hours are available on Monday and Thursday from 2:30-4:00 pm during the summer (email email@example.com to schedule a 30-minute virtual conversation).
SJSU researchers can still take advantage of the Extramural Funding Incentive Program.
Please note three new interesting COVID-19 related research opportunities from NIH on the Research Foundation’s COVID-19 opportunity list.
- Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19
- Research to Advance Vaccine Safety
- Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations
Advice from NIH and NSF Program Officers
While it is even more important than usual to connect with program officers before you apply to a grant, here’s some general advice from them:
- Do not delay your application; if you need to delay your start date, negotiate that after the grant is awarded.
- Keep your original plan, not a new plan based on COVID-19. Articulate your ideal plan, not a different plan due to COVID-19 (what you would like to do, not what you are forced to do). Tell what is beyond COVID-19.
- Include a contingency plan (depending upon the proposed start date). Think about how feasible those plans are if there is a second wave. Put these in an approach section, after aims and methods, and include potential challenges and alternative solutions.
- It is acceptable to reference publicly available COVID-19 (mitigation) plans, such as SJSU’s RSCA Revitalization and Adaptation Plan.
- This time provides an opportunity to be innovative and still advance work and have
- Keep in mind that POs are very busy, so when you do reach out to them provide concise, thoughtful ideas and plans. Offer your ideas for contingency planning.
- When talking to your PO, do your due diligence and check all stated resources first.
- Ask your PO what they expect to see in your contingency plans beyond what is in published resources. Ask how best to address what reviewers will want to see; you should have some possible strategies to offer.
Research Adaptations During COVID-19
Real-time adaptations to research processes and protocols to prevent the spread of COVID-19 were shared by CSU researchers and administrators during an hour and a half webinar on June 9th hosted by the California State University Chancellor’s Office of Research Department. Presenters and the audience discussed contingency planning for future RSCA.
Led by Leslie Poinciano, Director of Research Operations, Office of the Chancellor, presenters/topics include:
- Elizabeth Lowham, Cal Poly San Luis Obispo: The Cal Poly process for reviewing essential research proposals
- Trish Brock, Cal Poly San Luis Obispo: Changes in human subjects protocols
- Christine Valdez, CSU Monterey Bay: Trauma, loss, and growth during COVID-19
- Steve Blumenshine, Fresno State: Social distancing in the laboratory
- Chris Lowe, CSU Long Beach: Safety protocols for water-based equipment maintenance
- Matt Johnson, Humboldt State: The Quaranteam process for field-based data collection
The Archives: COVID-19 Funding News - as of June 1, 2020
"Endless Frontier Act" Proposes Expansion of NSF to ensure the U.S. Continues to Lead in Scientific and Technological Innovation
From the press release: Last week Congressman Ro Khanna (D-CA), Senate Democratic Leader Chuck Schumer (D-NY),
Senator Todd Young (R-IN), and Congressman Mike Gallagher (R-WI) unveiled the bipartisan,
bicameral Endless Frontier Act, an initiative to solidify the United States’ leadership
in scientific and technological innovation through increased investments in the discovery,
creation, and commercialization of technology fields of the future. The bipartisan
legislation further targets support to ensure new research investments translate into
new American companies, manufacturing and high-tech jobs, and opportunities for regions
across the country to become global centers of emerging technology industries.
The Endless Frontier Act proposes an expansion of the National Science Foundation (NSF)—to be renamed the National Science and Technology Foundation (NTSF)—and the establishment of a Technology Directorate within NTSF to advance technology in 10 critical focus areas. The newly-established Technology Directorate would receive $100 billion over five years to lead investment and research in artificial intelligence and machine learning; high performance computing; robotics, automation, and advanced manufacturing; and more. An additional $10 billion would be authorized to designate at least 10 regional technology hubs, awarding funds for comprehensive investment initiatives that position regions across the country to be global centers for the research, development, and manufacturing of key technologies.
"COVID-19: Five Things to Know About NIH NOSI Announcements" as reported by Willette B. Fatoyinbo, Program Manager at Grants Resource Center at The American Association of State Colleges and Universities
The National Institutes of Health (NIH) recently introduced a series of funding notices that it is using to attract innovative perspectives and approaches to the prevention of, preparation for, or response to the coronavirus (COVID-19) pandemic called the Notice of Special Interests (NOSI).
Here are five things you need to know about NOSI announcements:
NIH uses the NOSI in place of a program announcement. NOSI's allow NIH to streamline and package high-priority areas of research in one place. It is a special type of funding opportunity announcement (FOA).
Eligibility may vary with a NOSI, so review the notice carefully. For example, the Office of Strategic Coordination (OSC), which manages the Common Fund, received $30 million to expand COVID-19 research activities (over a five year period) in part due to the Coronavirus Aid, Relief, and Economic Security (CARES) Act. OSC is offering Emergency Competitive Revisions to active Common Fund grants and cooperative agreements, but starting in FY 21, the Common Fund will issue funding opportunities for researchers to develop new research projects. Nevertheless, other Offices and I/C's are now accepting new applications.
NOSI's point to existing parent announcements and FOA's. NOSIs currently replace institute/center (IC) issued program announcements to highlight interest in a research area. NOSI's will show an active list of I/C's involved in exploring the impact of COVID-19 in a variety of disciplines.
Timing is everything. NOSI's do expire. The notice will either highlight the expiration date or automatically expire on the original FOA date.
Don't forget to check the 4.b. box. NOSI applicants must include the notice number (e.g., NOTIC-EB-20-006) on 4.b. (Agency Routing Identifier question) of the SF424 application to ensure the application is assigned and tracked properly.
From NIH, you can also learn how to choose the right NIH funding opportunity.
Find the latest NOSIs on SJSURF’s Covid-19 Funding Opportunities List.
The Archives: Covid-19 Funding News – as of May 18, 2020
Additional Covid-19 Research Funding Anticipated in Newly Introduced HEROS Act
Ryan M. Ward, SJSU’s Director of Advocacy and Federal Relations, Office of the President, reports that another stimulus bill to address the effects of Covid-19 has been introduced by House Democrats. Senate Majority Leader Mitch McConnell (R-KY) said the Senate was in no rush to pass another COVID-19 relief package until the impact of the CARES Act (Phase III) had been fully assessed. Ultimately the Health and Economic Recovery Omnibus Emergency Solutions (HEROS) Act may look very different from the bill passed by the House, but this early Phase IV effort gives a sense of what may come. Allocations in this first Phase IV bill include provisions for funding to numerous research agencies to prevent, prepare for, and respond to COVID-19. The current HEROS Act bill provides $3 billion to the National Institutes of Health for offsetting the costs related to reductions in lab productivity resulting from COVID-19 and public health measure responses; there are also funding allocations for NSF, USGS, USFWS, and NEA. Info for this article was sourced from the Association of Public and Land Grant Universities.
NSF Civic Innovation Challenge Equips Communities for Greater Preparedness and Resilience to Natural Disasters
The Civic Innovation Challenge (CIVIC - NSF 20-562) is a research and action competition to build a more cohesive research-to-innovation
pipeline and foster a collaborative spirit. CIVIC will allow for a broader and more
fluid exchange of research interests and civic priorities; funded projects will produce
significant community impact within 12 months.
CIVIC has two tracks/topic areas: Offering Better Mobility Options to Solve the Spatial Mismatch Between Housing Affordability, and Equipping Communities for Greater Preparedness and Resilience to Natural Disasters. The two-stage competition is funded at $50,000 for the four-month planning phase and up to $1,000,000 for stage 2. Applications are due July 01, 2020.
AERA and Spencer Foundation Will Examine the Impact of the COVID-19 Pandemic on the Education Research Field
The American Educational Research Association (AERA) - the largest national interdisciplinary research association devoted to the scientific
study of education and learning - and the Spencer Foundation are undertaking a study of the impact of COVID-19 on
early career scholars and graduate students in education research—the most professionally
vulnerable of the field. The American Educational Research Association and Spencer plan to release an initial report in July. Focus groups will be conducted
in May and will be followed by an online survey in early June.
The project, “Centering the Needs of Early Career Scholars and Graduate Students in Education Research: An AERA-Spencer Inquiry into the COVID-19 Pandemic Impacts,” will assess the pressing needs facing these individuals and what might be important in a “recovery plan” for addressing them. The study broadly examines the effects of COVID-19 on current employment or academic situations and career advancement; financial strains and their impact on academic/career progress; the challenges of navigating professional and personal lives; how teaching, mentoring, and advising roles are being transformed; the impact on areas of research and the availability of data; the ability to continue with meaningful research; and the forms of support—social and material—that will enable moving forward in the face of substantially altered and pernicious circumstances.
The Archives: COVID-19 Funding News - as of May 5, 2020
California Humanities Funding Announcement and Webinar Session
In recognition that the COVID-19 pandemic has had a serious impact on the public humanities field across the state, California Humanities will direct funds from the federal CARES Act, through the National Endowment for the Humanities, to meet the emergency relief needs of organizations and individuals in order to help sustain and grow the public humanities field in California. Eligible individuals and organizations applicant organizations must demonstrate a track record for supporting rich and engaging public humanities work that is accessible to the people of California.
In keeping with California Humanities’ mission to connect Californians to ideas and one another in order to understand our shared heritage and diverse cultures, inspire civic participation, and shape our future, California Humanities relief and recovery grants aim to provide support to organizations that have experienced the cancellation of their public humanities activities due to a decrease or loss of revenue, programming opportunities, loss of paid staff, or venues as a result of COVID-19, as well as to humanities practitioners who are facing financial hardship. Funding from the State of California will provide capacity-building recovery grants to assist organizations as they consider new approaches to public humanities programming and organizational strength.
There will be an Applicant Webinar titled CA CARES: Humanities Relief and Recovery Grants on Friday, May 8 from 11am to 12pm.
Due dates, registration for the webinar, and other information can be found at: https://calhum.org/funding-opportunities/ca-cares-humanities-relief-and-recovery-grants/
ED Opens Education and Special Education Research Competitions
The U.S. Department of Education's (ED) Institute of Education Sciences (IES) has opened competitions for eight research and special education research grants programs - the agency's primary education research funding mechanisms.
Four of the competitions are offered through the IES National Center for Education Research (NCER): Education Research; Education Research Training; Education Research and Development Centers; and Systematic Replication in Education. The other four competitions are offered through the IES National Center for Special Education Research (NCSER): Special Education Research; Special Education Research Training; National Assessment of Educational Progress Process Data; and Systematic Replication in Special Education.
Applications are due August 20, 2020. Award amounts vary by competition. Identify a current funding opportunity that matches your research interests and identify the relevant Letter of Intent and application deadlines. You can also view a prerecorded funding opportunities webinar to learn more about the application process and choosing an appropriate funding opportunity. Letters of Intent are optional but suggested. Download the Application Submission Guide [pdf], as well as the appropriate Request for Applications and application package (Search for CFDA 84.305 or CFDA 84.324) for more info.
NIAID Announces News Strategic Plan Amid Covid-19 Crisis
NIAID’s Strategic Plan for COVID-19 Research [pdf] (National Institute of Allergy and Infectious Diseases), part of the National Institutes of Health (NIH), details the urgency for accelerating research to diagnose, prevent and treat COVID-19.
The NIAID Strategic Plan for COVID-19 Research has four key priorities. The first involves improving fundamental knowledge of SARS-CoV-2 and COVID-19, including studies to characterize the virus and better understand how it causes infection and disease. This research includes natural history, transmission and surveillance studies to determine why some individuals experience mild symptoms of infection while others become critically ill. The role of asymptomatic individuals in viral spread and the potential seasonality of viral circulation also need to be explored, according to the report.
NIAID’s second research priority is the development of rapid, accurate diagnostics and assays to identify and isolate COVID-19 cases and track the spread of the virus. Molecular assays can detect low levels of SARS-CoV-2 and differentiate it from other related viruses. Researchers will work to improve the speed and accuracy of these diagnostic assays to mitigate the spread of the disease during the current outbreak and any future ones. Additionally, new and improved serologic assays to detect antibodies to the virus must be developed to enhance surveillance efforts and identify individuals who may have resolved a previous COVID-19 infection.
The third research priority is characterizing and testing potential treatments for COVID-19. These efforts will include identifying and evaluating drugs already approved for other conditions that could be repurposed to treat COVID-19 and testing novel broad-spectrum antivirals, such as remdesivir; virus-targeted antibody-based therapies; monoclonal antibodies; and host-directed strategies to target an individual’s immune response to the virus.
NIAID’s fourth research priority is to develop safe and effective vaccines to protect individuals from infection and prevent future SARS-CoV-2 outbreaks. NIAID researchers and their collaborators are adapting vaccine candidates and approaches previously employed to address the related Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) coronaviruses and applied them to the current pandemic.
NIAID recently launched a Phase 1 clinical trial using a vaccine platform initially developed to target MERS. NIAID will use its broad clinical trial infrastructure to advance experimental vaccines through Phase 1 safety and dosing testing and simultaneously plan for advanced clinical testing of the most promising candidates. The institute will work with government partners to ensure that any safe and effective vaccine will be manufactured in sufficient quantities to allow expedient distribution to those at highest risk for infection.
The Archives: Covid-19 Funding News – as of April 21, 2020
National Institutes of Health (NIH) Covid-19 Emergency Funding
NIH is issuing new COVID-19 related NOSIs (Notice of Special Interest) frequently. Check Covid-19-related information on the NIH Coronavirus Disease 2019 (COVID-19) website https://grants.nih.gov/policy/natural-disasters/corona-virus.htm.
In addition to dedicating regularly appropriated funds, to date NIH has received emergency funding for COVID-19-related activities in two supplemental bills (available from the NIH Office of Budget website), that together provide:
$1.532 billion for NIAID - National Institute of Allergy and Infectious Diseases
$103.4 million for NHLBI – National Heart and Lung Institute
$60 million for NIBIB - National Institute of Biomedical Imaging and Bioengineering
$36 million for NCATS - National Center for Advancing Translational Sciences
$30 million for the NIH - Office of the Director
$10 million for NIEHS - National Institute of Environmental Health Sciences
$10 million for NLM – National Library of Medicine
To get funding as quickly as possible to the research community, NIH is using Urgent and Emergency competing revisions and administrative supplements to existing grant awards. This approach allows NIH to leverage resident expertise, getting additional funding to researchers who are already working with other organisms, models, or tools so that they can quickly shift focus to the novel coronavirus. These Urgent and Emergency Competitive Revision Funding Opportunity Announcements (FOAs) allow NIH to fund applications quickly, often in under three months, as evaluation for scientific and technical merit is done by an internal review panel convened by staff of the NIH awarding institute or center rather than by NIH’s traditional peer review process.
The Urgent and Emergency competing revision FOAs are very similar, but Emergency Competitive Revisions Emergency Competitive Revision FOA can only be used for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster; for COVID-19 funding, funds can only be distributed by those NIH Institutes and Centers listed above that received special emergency funding.
Urgent Competitive Revisions Urgent Competitive Revision FOA can be used to meet immediate needs to help address a specific public health crisis in a timely manner. This vehicle is used to help address a specific public health crisis that was unforeseen when the application or progress report was submitted.
There are specific review criteria specified in each FOA as well as in each NOSI. Learn more about NOSI’s in this quick 5 minute video. https://www.youtube.com/watch?v=LhXW67LNbIc
National Science Foundation (NSF) Convergence Accelerator
The NSF Convergence Accelerator announced the release of the 2020 Phase I and II Program Solicitation (NSF 20-565 [pdf]).
The new multi-disciplinary structure is unique to NSF and the Federal Government. The program – using two tracks of NFS’s Big Ideas Program, see below – aims to test out new models of innovation in government, industry and academia by seeding basic problem solving research via teams of scientists, business practitioners, and nonprofit leaders.
Learn more in a 3 minute video. https://www.nsf.gov/od/oia/convergence-accelerator/
The 2020 NSF Convergence Accelerator consists of two tracks as follows: Quantum Technology (Track C) and AI-Driven Innovation via Data and Model Sharing (Track D). NSF 20-565 [pdf] contains detailed descriptions of these two tracks and NSF’s expectations of submissions. A Preliminary Proposal (PP) is required by May 11, 2020; an unlimited number of PPs is allowed. Successful Phase I proposals will be invited to submit a full proposal by July 10, 2020. Phase I awards are expected to occur in September 2020 and awardees will participate in Cohort activities for nine months. Phase I teams will participate in the Convergence Accelerator curriculum, which pushes them to identify and expand partnerships with end-users, other stakeholders, and other teams, allowing them to refine their plans for Phase II. All Phase II proposals must be built upon a foundation developed by one or more Phase I awards. Phase II proposals will occur in Spring 2021.
United States Department of Education (ED) SEED and EIR Mid-Phase Grants Programs
The U.S. Department of Education (ED) recently opened two competitions of interest to colleges and universities: one supporting teacher development efforts (SEED) and the other funding the implementation and evaluation of education innovations (EIR Mid-Phase).
The Supporting Effective Educator Development (SEED) Program provides funding to develop and increase the number of highly effective educators. These grants will allow eligible entities to develop, expand, and evaluate practices that can serve as models to be sustained and disseminated. A college or university is eligible to apply if it provides course materials or resources that are evidence-based in increasing academic achievement, graduation rates, or rates of postsecondary education matriculation.
ED estimates there will be seven to ten awards averaging $3.5 million per year for projects lasting up to 36 months. ED encourages applicants to submit optional notices of intent, due May 13, 2020, while full applications are due June 12, 2020.
The Education Innovation and Research (EIR) Mid-phase Grants provide funding to create, develop, implement, replicate, or take to scale entrepreneurial, evidence-based, field-initiated innovations to improve student achievement and attainment for high-need students; and rigorously evaluate such innovations. There are three types of EIR grants – Early-phase, Mid-phase, and Expansion grants – however, the current announcement is for Mid-phase grants only. Mid-phase grants are intended to fund implementation and a rigorous evaluation of a program that has been successfully implemented under an Early-phase grant or other effort meeting similar criteria, for the purpose of measuring the program's impact and cost-effectiveness. Colleges and universities are eligible to apply if they partner with other eligible applicants (including local or state educational agencies, and others).
ED estimates that 16 to 20 awards averaging about $8 million each are available for projects potentially lasting up to 60 months. ED encourages applicants to submit optional notices of intent, due April 30, 2020, while full applications are due June 15, 2020. Additional information for applicants will be posted on the program website.
While ED doesn't anticipate a competition for Expansion grants in FY 20, it does plan to open competition for EIR Early-phase grants later this fiscal year. View the full funding announcement in the Federal Register. A request for comments related to priorities for future EIR competitions is available here.
The Archives: Covid-19 Funding News – as of April 10, 2020
Cares Act Summary
We are monitoring the $2 trillion Cares Act, which was signed into law on March 27; it was the third (and largest) legislative package passed in response to the COVID-19 epidemic. Allocations include:
- $75 million in supplemental funding for the National Endowment for the Humanities (NEH) to support humanities institutions and programs affected by COVID-19 (coronavirus); this funding is in addition to NEH's FY 2020 appropriation of $162.25 million.
- $945 million for the National Institutes of Health, of which $706 million is for the National Institute of Allergy and Infectious Diseases
- $103 million for the National Heart, Lung, and Blood Institute
- $60 million for the National Institute of Biomedical Imaging and Bioengineering
- $36 million for the National Center for Advancing Translational Sciences
- $30 million for the Office of the Director
- $10 million for the National Library of Medicine
- $415 million for the U.S. Department of Defense's health R&D activities, including the development of vaccines, anti-viral drugs, and diagnostic tests
- $99.5 million for the U.S. Department of Energy
- $76 million to the National Science Foundation
- $66 million for the National Institute of Standards and Technology
Please note that the Cares Act also has funding provisions for Title III and Hispanic Serving Institutions (HSI), of which SJSU qualifies, in the amount of approximately $300 million.
The National Science Foundation (NSF)
NSF is particularly encouraging the submission of proposals that conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge. They are encouraging applications through both existing funding mechanisms and the RAPID funding mechanism as described in this Dear Colleague Letter [pdf].
NSFs Division of Undergraduate Education (DUE) is specifically interested in research on the impact of the COVID-19 outbreak on undergraduate education. Possible topics of interest for these funding mechanisms include, but are not limited to, research on the effectiveness of switching from an in-person to a completely online educational format and research on how the outbreak affects student attitudes, interests, and performance in STEM. DUE is encouraging submission of RAPID proposals, requests for supplemental support of existing awards, and submissions to organize a conference or workshop.
They are also encouraging Phase I SBIR and STTR focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis as described in this Dear Colleague Letter [pdf].
The National Institutes of Health (NIH)
NIH has the most funding opportunities for COVID-19 at the current time. Opportunities range from training programs to countermeasures against pathogens and are detailed on the Research Foundation website.
The National Endowment for the Arts (NEA)
NEA is focused on, and closely monitoring, COVID-19 and its effect on the arts community. They have cancelled the application deadline for Challenge America to prepare for distribution of funding from the CARES Act in the amount of $75 million. Challenge America applicants should apply for Grants for Arts Projects with a deadline of July 9, 2020.
The National Endowment for the Humanities (NEH) application and deadline process has not been impacted by the Covid-19 pandemic. They will be awarding an additional $75 million directly to jurisdictional humanities councils in support of cultural nonprofits and educational programming.